SCHEMBL3597562

SCHEMBL3597562

COCc1nn(C)c(Oc2cc(OCc3ccc(OC)cc3)c(Cl)cc2Cl)c1C=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 5/20 0.39
CYP1A2 P05177 3/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
HDAC8 Q9BY41 1/20 0.35
CTSL P07711 1/20 0.34
CTSB P07858 1/20 0.34
LMNA P02545 3/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
POLB P06746 1/20 0.34
CYP3A4 P08684 1/20 0.34
MRGPRX4 Q96LA9 1/20 0.33
EGFR P00533 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604969 0.92 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3605696 0.91 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3612420 0.88 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3603078 0.86 SMN1; SMN2 (0.38) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3614214 0.85 MAPT (0.40) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3611047 0.85 CYP1A2 (0.43) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3605828 0.85 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3616648 0.84 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3604721 0.84 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3605167 0.84 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R SMN1; SMN2 4515/4885ALDH1A1 365/4885CYP1A2 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.